ArticleRespirology (Carlton, Vic.)2017
Patients hospitalized with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics.
Article in Respirology (Carlton, Vic.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Clinical Outcome Prediction by High-Resolution Computed Tomography and Echocardiography Assessment of Pulmonary Hypertension in Patients with Bronchiectasis.Tuberculosis and respiratory diseases · 2026Article
- Sputum microbiology data and related clinical outcomes among adult Aboriginal Australians with bronchiectasis.Internal medicine journal · 2025Article
- Association between pulmonary function and rapid kidney function decline: a longitudinal cohort study from CHARLS.BMJ open respiratory research · 2024Article
- Factors influencing survival and mortality among adult Aboriginal Australians with bronchiectasis-A 10-year retrospective study.Frontiers in medicine · 2024Article
- Do Patients with Bronchiectasis Have an Increased Risk of Developing Lung Cancer? A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Insights into Personalised Medicine in Bronchiectasis.Journal of personalized medicine · 2023Review
- Impacts of Asthma in Patients With Bronchiectasis: Findings From the KMBARC Registry.Allergy, asthma & immunology research · 2023Article
- The Role of Impulse Oscillometry in Evaluating Disease Severity and Predicting the Airway Reversibility in Patients With Bronchiectasis.Frontiers in medicine · 2022Article
- Antimicrobial Resistance in Common Respiratory Pathogens of Chronic Bronchiectasis Patients: A Literature Review.Antibiotics (Basel, Switzerland) · 2021Review
- Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis.Respiratory research · 2019Article
- Arterial stiffness in adults with steady-state bronchiectasis: association with clinical indices and disease severity.Respiratory research · 2018Article
- Lung Function and Incident Kidney Disease: The Atherosclerosis Risk in Communities (ARIC) Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Article
- Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study.Respiratory research · 2017Observational
- Patients hospitalized with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics.Respirology (Carlton, Vic.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveBronchiectasis is a growing health burden both globally and in Australasia. Associated with repeated respiratory infections, the disease often results in hospital admission, impaired quality of life, reduced lung function and shortened life expectancy. We describe the local clinical, physiological and sputum characteristics in patients hospitalized with an infective exacerbation of bronchiectasis.
methodsThis study examined the medical records of all 61 adults admitted to a metropolitan Australian hospital with an infective exacerbation of bronchiectasis in a calendar year.
resultsBaseline characteristics include: mean (SD) age of participants was 66 (14) years; 56% were women and 42% were current or ex-smokers. The majority had other coexisting medical conditions, with asthma in 44%, COPD in 59% and both asthma and COPD in 31%. Seventy-two percent were on regular inhaled medication, 23% on cyclical antibiotics and 26% undertook regular respiratory physiotherapy. Bronchodilator reversibility was present in 17% and small airway reversibility in 41%. Sputum demonstrated normal flora in 17%, Pseudomonas aeruginosa in 32%, Haemophilus influenzae in 15% and both organisms in 17%. Mean numbers of exacerbations per year requiring hospitalization was 2.3. Sixty-two percent of subjects had an Index of Relative Socio-Economic Disadvantage in deciles 1-5. Risk factors for exacerbations included a history of asthma or COPD, documented small airway reversibility and presence of P. aeruginosa.
conclusionPatients hospitalized with an infective exacerbation of bronchiectasis are predominantly older with co-morbidities and of lower socio-economic status. Presence of P. aeruginosa was a risk factor for repeated exacerbations, as was a history of asthma, COPD or small airway reversibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.